"Cytodyn... today announced it is offering comprehensive cytokine profiling (including RANTES levels) through its diagnostic partner company, IncellDx, to help physicians understand the pathogenesis of Childhood Inflammatory Disease Related to COVID-19. These laboratory tests are exploratory in nature and not intended for clinical decision making."
I bring this up because MESO was able to save a 4 yr old patient who had MIS-C brought upon by COVID and am certain Leronlimab can help too. MESO just received 9-1 vote in favor of FDA approval for a single arm study because it involved child mortality. All the forces working against Leronlimab could be negated when going against health & safety of children. From a purely strategic standpoint, this would have been the most sure thing on the path to approval IMO.
https://web.musc.edu/about/news-center/2020/0...s-hospital